{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:45:17Z","timestamp":1791251117857,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,19]]},"DOI":"10.7759\/cureus.107347","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T16:25:44Z","timestamp":1776615944000},"source":"Crossref","is-referenced-by-count":1,"title":["New Horizons in IgA Nephropathy: Approach to Current and Emerging Therapies"],"prefix":"10.7759","author":[{"given":"Sai Kumar","family":"Madhavaram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samyuktha","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A","family":"Bhanushali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638309","article-title":"Alternative complement pathway is activated and associated with galactose-deficient IgA1 antibody in IgA nephropathy patients","volume":"12","author":"Chiu YL","year":"2021","unstructured":"Chiu YL, Lin WC, Shu KH, et al.. Alternative complement pathway is activated and associated with galactose-deficient IgA1 antibody in IgA nephropathy patients. Front Immunol. 2021, 12:638309. 10.3389\/fimmu.2021.638309","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette R","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, et al.. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023, 402:859-70. 10.1016\/S0140-6736(23)01554-4","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13477","article-title":"High levels of urinary complement proteins are associated with chronic renal damage and proximal tubule dysfunction in immunoglobulin A nephropathy","volume":"24","author":"Wen L","year":"2019","unstructured":"Wen L, Zhao Z, Wang Z, Xiao J, Birn H, Gregersen JW. High levels of urinary complement proteins are associated with chronic renal damage and proximal tubule dysfunction in immunoglobulin A nephropathy. Nephrology (Carlton). 2019, 24:703-10. 10.1111\/nep.13477","journal-title":"Nephrology (Carlton)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017010108","article-title":"Remission of hematuria improves renal survival in IgA nephropathy","volume":"28","author":"Sevillano AM","year":"2017","unstructured":"Sevillano AM, Guti\u00e9rrez E, Yuste C, et al.. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol. 2017, 28:3089-99. 10.1681\/ASN.2017010108","journal-title":"J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher D","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, et al.. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023, 18:727-38. 10.2215\/CJN.0000000000000135","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin BH","year":"2025","unstructured":"Rovin BH, Barratt J, Cook HT, et al.. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). Kidney Int. 2025, 108:S1-71. 10.1016\/j.kint.2025.04.004","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003962.pub2","article-title":"Non-immunosuppressive treatment for IgA nephropathy","author":"Reid S","year":"2011","unstructured":"Reid S, Cawthon PM, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2011, CD003962. 10.1002\/14651858.CD003962.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin BH","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, et al.. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023, 402:2077-90. 10.1016\/S0140-6736(23)02302-4","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur M","year":"2024","unstructured":"Mathur M, Barratt J, Chacko B, et al.. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2024, 390:20-31. 10.1056\/NEJMoa2305635","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.01.014","article-title":"Treatment of patients with IgA nephropathy: a call for a new paradigm","volume":"107","author":"Floege J","year":"2025","unstructured":"Floege J, Bernier-Jean A, Barratt J, Rovin B. Treatment of patients with IgA nephropathy: a call for a new paradigm. Kidney Int. 2025, 107:640-51. 10.1016\/j.kint.2025.01.014","journal-title":"Kidney Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.026","article-title":"Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung AK","year":"2021","unstructured":"Cheung AK, Chang TI, Cushman WC, et al.. Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021, 99:559-69. 10.1016\/j.kint.2020.10.026","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00888-3","article-title":"Current treatment of IgA nephropathy","volume":"43","author":"Floege J","year":"2021","unstructured":"Floege J, Rauen T, Tang SC. Current treatment of IgA nephropathy. Semin Immunopathol. 2021, 43:717-28. 10.1007\/s00281-021-00888-3","journal-title":"Semin Immunopathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.08.013","article-title":"Risks and benefits of different dietary patterns in CKD","volume":"81","author":"Joshi S","year":"2023","unstructured":"Joshi S, Kalantar-Zadeh K, Chauveau P, Carrero JJ. Risks and benefits of different dietary patterns in CKD. Am J Kidney Dis. 2023, 81:352-60. 10.1053\/j.ajkd.2022.08.013","journal-title":"Am J Kidney Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti P","year":"1999","unstructured":"Ruggenenti P, Perna A, Gherardi G, et al.. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999, 354:359-64. 10.1016\/S0140-6736(98)10363-X","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/01.asn.0000068460.37369.dc","article-title":"Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial","volume":"14","author":"Praga M","year":"2003","unstructured":"Praga M, Guti\u00e9rrez E, Gonz\u00e1lez E, Morales E, Hern\u00e1ndez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003, 14:1578-83. 10.1097\/01.asn.0000068460.37369.dc","journal-title":"J Am Soc Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(99)70416-6","article-title":"Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy","volume":"33","author":"Russo D","year":"1999","unstructured":"Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis. 1999, 33:851-6. 10.1016\/s0272-6386(99)70416-6","journal-title":"Am J Kidney Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler DC","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, et al.. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021, 100:215-24. 10.1016\/j.kint.2021.03.033","journal-title":"Kidney Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr349","article-title":"Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study","volume":"27","author":"Tang SC","year":"2012","unstructured":"Tang SC, Lin M, Tam S, et al.. Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrol Dial Transplant. 2012, 27:613-8. 10.1093\/ndt\/gfr349","journal-title":"Nephrol Dial Transplant"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington WG","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al.. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023, 388:117-27. 10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJL","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14061960","article-title":"SGLT2 inhibitors and the risk of urogenital infections: a concise review","volume":"14","author":"Confederat LG","year":"2025","unstructured":"Confederat LG, Dragostin OM, Condurache MI. SGLT2 inhibitors and the risk of urogenital infections: a concise review. J Clin Med. 2025, 14:1960. 10.3390\/jcm14061960","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.34485","article-title":"SGLT2 inhibitors and external genital infection in male patients with type 2 diabetes","volume":"8","author":"Cheng TH","year":"2025","unstructured":"Cheng TH, Lin KC, Chuang AT, et al.. SGLT2 inhibitors and external genital infection in male patients with type 2 diabetes. JAMA Netw Open. 2025, 8:e2534485. 10.1001\/jamanetworkopen.2025.34485","journal-title":"JAMA Netw Open"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01256-9","article-title":"Risk of urinary tract infection in patients with type 2 diabetes mellitus treated with dapagliflozin: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Zheng Z","year":"2023","unstructured":"Zheng Z, He D, Chen J, Xie X, Lu Y, Wu B, Jiang X. Risk of urinary tract infection in patients with type 2 diabetes mellitus treated with dapagliflozin: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2023, 43:209-25. 10.1007\/s40261-023-01256-9","journal-title":"Clin Drug Investig"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.08.007","article-title":"The treatment of primary IgA nephropathy: change, change, change","volume":"83","author":"Caster DJ","year":"2024","unstructured":"Caster DJ, Lafayette RA. The treatment of primary IgA nephropathy: change, change, change. Am J Kidney Dis. 2024, 83:229-40. 10.1053\/j.ajkd.2023.08.007","journal-title":"Am J Kidney Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan DE","year":"2014","unstructured":"Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 2014, 86:896-904. 10.1038\/ki.2014.143","journal-title":"Kidney Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen T","year":"2020","unstructured":"Rauen T, Wied S, Fitzner C, et al.. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020, 98:1044-52. 10.1016\/j.kint.2020.04.046","journal-title":"Kidney Int"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1159\/000519812","article-title":"The therapeutic evaluation of steroids in IgA nephropathy global (TESTING) study: trial design and baseline characteristics","volume":"52","author":"Wong MG","year":"2021","unstructured":"Wong MG, Lv J, Hladunewich MA, et al.. The therapeutic evaluation of steroids in IgA nephropathy global (TESTING) study: trial design and baseline characteristics. Am J Nephrol. 2021, 52:827-36. 10.1159\/000519812","journal-title":"Am J Nephrol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-5-3","article-title":"A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]","volume":"5","author":"Hogg RJ","year":"2004","unstructured":"Hogg RJ, Wyatt RJ. A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]. BMC Nephrol. 2004, 5:3. 10.1186\/1471-2369-5-3","journal-title":"BMC Nephrol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020513","article-title":"Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria","volume":"99","author":"Pei G","year":"2020","unstructured":"Pei G, Tan J, Tang Y, et al.. Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria. Medicine (Baltimore). 2020, 99:e20513. 10.1097\/MD.0000000000020513","journal-title":"Medicine (Baltimore)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4103\/0971-4065.107197","article-title":"Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome","volume":"23","author":"Sinha A","year":"2013","unstructured":"Sinha A, Sharma A, Mehta A, et al.. Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome. Indian J Nephrol. 2013, 23:41-6. 10.4103\/0971-4065.107197","journal-title":"Indian J Nephrol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-024-02029-z","article-title":"Hydroxychloroquine blood concentrations and effects in Chinese patients with IgA nephropathy","volume":"37","author":"Yang T","year":"2024","unstructured":"Yang T, Shi Y, Wang Y, et al.. Hydroxychloroquine blood concentrations and effects in Chinese patients with IgA nephropathy. J Nephrol. 2024, 37:2201-8. 10.1007\/s40620-024-02029-z","journal-title":"J Nephrol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu LJ","year":"2019","unstructured":"Liu LJ, Yang YZ, Shi SF, et al.. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2019, 74:15-22. 10.1053\/j.ajkd.2019.01.026","journal-title":"Am J Kidney Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70382","article-title":"Immunoglobulin A nephropathy: molecular pathogenesis and targeted therapy","volume":"6","author":"Zhou XJ","year":"2025","unstructured":"Zhou XJ. Immunoglobulin A nephropathy: molecular pathogenesis and targeted therapy. MedComm (2020). 2025, 6:e70382. 10.1002\/mco2.70382","journal-title":"MedComm (2020)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.12.007","article-title":"A targeted-release formulation of budesonide for the treatment of IgA nephropathy patients with severe renal impairment","volume":"10","author":"Ouyang Y","year":"2025","unstructured":"Ouyang Y, Zhao Y, Chen M, et al.. A targeted-release formulation of budesonide for the treatment of IgA nephropathy patients with severe renal impairment. Kidney Int Rep. 2025, 10:935-9. 10.1016\/j.ekir.2024.12.007","journal-title":"Kidney Int Rep"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017060713","article-title":"Effects of two immunosuppressive treatment protocols for IgA nephropathy","volume":"29","author":"Rauen T","year":"2018","unstructured":"Rauen T, Fitzner C, Eitner F, et al.. Effects of two immunosuppressive treatment protocols for IgA nephropathy. J Am Soc Nephrol. 2018, 29:317-25. 10.1681\/ASN.2017060713","journal-title":"J Am Soc Nephrol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000534","article-title":"Efficacy and safety of ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial","volume":"36","author":"Lafayette R","year":"2025","unstructured":"Lafayette R, Tumlin J, Fenoglio R, et al.. Efficacy and safety of ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial. J Am Soc Nephrol. 2025, 36:645-56. 10.1681\/ASN.0000000534","journal-title":"J Am Soc Nephrol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.31.5.499","article-title":"Cost-effectiveness analysis of targeted-release formulation of budesonide (Tarpeyo) in conjunction with optimized renin-angiotensin system inhibitor (RASi) therapy relative to optimized RASi therapy alone for adults with primary immunoglobulin A nephropathy in the United States","volume":"31","author":"Yaghoubi M","year":"2025","unstructured":"Yaghoubi M, Jiang H, Casciano R, Ngai C, Patel M. Cost-effectiveness analysis of targeted-release formulation of budesonide (Tarpeyo) in conjunction with optimized renin-angiotensin system inhibitor (RASi) therapy relative to optimized RASi therapy alone for adults with primary immunoglobulin A nephropathy in the United States. J Manag Care Spec Pharm. 2025, 31:499-509. 10.18553\/jmcp.2025.31.5.499","journal-title":"J Manag Care Spec Pharm"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.09.031","article-title":"Evaluating sibeprenlimab in IgA nephropathy - rationale and baseline data from the VISIONARY trial","volume":"10","author":"Perkovic V","year":"2025","unstructured":"Perkovic V, Barratt J, Lafayette R, et al.. Evaluating sibeprenlimab in IgA nephropathy - rationale and baseline data from the VISIONARY trial. Kidney Int Rep. 2025, 10:4207-18. 10.1016\/j.ekir.2025.09.031","journal-title":"Kidney Int Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette R","year":"2024","unstructured":"Lafayette R, Barbour S, Israni R, et al.. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024, 105:1306-15. 10.1016\/j.kint.2024.03.012","journal-title":"Kidney Int"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01320-2","article-title":"Role of telitacicept in the treatment of IgA nephropathy","volume":"28","author":"Wu L","year":"2023","unstructured":"Wu L, Du X, Lu X. Role of telitacicept in the treatment of IgA nephropathy. Eur J Med Res. 2023, 28:369. 10.1186\/s40001-023-01320-2","journal-title":"Eur J Med Res"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic V","year":"2025","unstructured":"Perkovic V, Barratt J, Rovin B, et al.. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med. 2025, 392:531-43. 10.1056\/NEJMoa2410316","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.01.144","article-title":"POS-132 Trial design: phase 3 randomized, double-blind, placebo-controlled study of narsoplimab safety and efficacy in IgA nephropathy (ARTEMIS-IGAN)","volume":"7","author":"Lafayette R","year":"2022","unstructured":"Lafayette R, Rovin B, Floege J, Tesar V, Zhang H, Barratt J. POS-132 Trial design: phase 3 randomized, double-blind, placebo-controlled study of narsoplimab safety and efficacy in IgA nephropathy (ARTEMIS-IGAN). Kidney Int Rep. 2022, 7:S57. 10.1016\/j.ekir.2022.01.144","journal-title":"Kidney Int Rep"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13040947","article-title":"An update on current therapeutic options in IgA nephropathy","volume":"13","author":"Lim RS","year":"2024","unstructured":"Lim RS, Yeo SC, Barratt J, Rizk DV. An update on current therapeutic options in IgA nephropathy. J Clin Med. 2024, 13:947. 10.3390\/jcm13040947","journal-title":"J Clin Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1297352","article-title":"Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders","volume":"14","author":"Dudler T","year":"2023","unstructured":"Dudler T, Yaseen S, Cummings WJ. Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders. Front Immunol. 2023, 14:1297352. 10.3389\/fimmu.2023.1297352","journal-title":"Front Immunol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3699-z","article-title":"New insights into the pathogenesis of IgA nephropathy","volume":"33","author":"Yeo SC","year":"2018","unstructured":"Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol. 2018, 33:763-77. 10.1007\/s00467-017-3699-z","journal-title":"Pediatr Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/425929-new-horizons-in-iga-nephropathy-approach-to-current-and-emerging-therapies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T16:25:45Z","timestamp":1776615945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/425929-new-horizons-in-iga-nephropathy-approach-to-current-and-emerging-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.107347","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,19]]}}}